Aytu BioPharma opened at $1.81, in line with its previous close of $1.81. In the last trading session, the stock traded between $1.77 and $1.91. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Aytu BioPharma is now worth
$ 3.68
Resulting in a loss of
$ 96.32 (96.32%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.03 (-1.66%)
Day High
$1.91
Day Low
$1.77
Day Open
$1.81
Prev Close
$1.81
Volume
22,575
1W Return
-5.82%
1M Return
-10.33%
3M Return
-26.14%
6M Return
-27.05%
1Y Return
-15.24%
Fundamentals
Market Cap ($ Mn)
19
PE Ratio
-
PB Ratio
0.69
PEG Ratio
-
ROE
-49.88%
ROCE
-18.11%
EPS (TTM)
$0.00
Investment Returns
1 Week
-5.82%
1 Month
-10.33%
3 Months
-26.14%
6 Months
-27.05%
9 Months
-21.59%
Financials
Quarterly
All values in $ Mn
18.5
Mar 25
15.1
Jun 25
13.9
Sep 25
15.2
Dec 25
12.4
Mar 26
16.1
Jun 26
Updates
23Sep
Aytu BioPharma Q4FY26 Results: Sales up 6.4% YoY to $16.1M
Q4FY26 revenue rose 6.4% YoY to $16.1 million, beating analyst estimates by 31%. EXXUA prescriptions grew 138% QoQ to 3,323, with monthly run-rate hitting 1,408 in August. FY27 operating expenses guided at $49-54 million, with $6 million deferred from FY26 for EXXUA marketing. Adjusted EBITDA turned positive in Q4 at $0.5 million, with management expecting positive EBITDA for H1FY27.
1mo ago
26Jun
Aytu BioPharma and Lannett terminate Metadate agreement
Aytu BioPharma and Lannett terminated their Metadate agreement effective June 23, 2026. Aytu will continue selling existing inventory and pay royalties until sales cease.
4mo ago
11Jun
Ascendiant Capital raises Aytu BioPharma target to $14.5
Ascendiant Capital analyst Edward Woo maintained a Buy rating on Aytu BioPharma and raised the price target to $14.5 from $14, signaling increased confidence in the stock's valuation.
